TDC
PFE icon

Thompson Davis & Co’s Pfizer PFE Stock Holding History

Thompson Davis & Co’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,500
Closed -$446K – 103
2022
Q2 		$446K Hold
8,500
– – 0.73% 31
2022
Q1 		$440K Sell
8,500
-1,825
-18% -$94.7K 0.54% 43
2021
Q4 		$610K Buy
+10,325
New +$512K 0.51% 33
2018
Q3 		$20K Sell
474
-633
-57% -$24.4K 0.04% 330
2018
Q2 		$38K Buy
1,107
+127
+13% +$4.34K 0.09% 234
2018
Q1 		$33K Sell
980
-432
-31% -$14.9K 0.09% 230
2017
Q4 		$49K Sell
1,412
-2,553
-64% -$87.1K 0.12% 186
2017
Q3 		$134K Sell
3,965
-4,045
-50% -$130K 0.24% 96
2017
Q2 		$255K Sell
8,010
-1,102
-12% -$34.8K 0.41% 61
2017
Q1 		$296K Buy
9,112
+939
+11% +$29.6K 0.42% 57
2016
Q4 		$252K Sell
8,173
-280
-3% -$8.55K 0.42% 57
2016
Q3 		$272K Sell
8,453
-452
-5% -$15.1K 0.48% 45
2016
Q2 		$297K Sell
8,905
-15,340
-63% -$490K 0.47% 42
2016
Q1 		$682K Buy
24,245
+8,587
+55% +$245K 1.02% 8
2015
Q4 		$480K Buy
15,658
+11,804
+306% +$371K 0.68% 20
2015
Q3 		$115K Sell
3,854
-34,186
-90% -$1.1M 0.16% 148
2015
Q2 		$1.21M Buy
38,040
+23,112
+155% +$753K 1.4% 8
2015
Q1 		$493K Buy
14,928
+7,702
+107% +$245K 0.59% 26
2014
Q4 		$214K Sell
7,226
-23,112
-76% -$663K 0.25% 80
2014
Q3 		$851K Buy
30,338
+29,172
+2,502% +$819K 1.1% 12
2014
Q2 		$33K Sell
1,166
-103
-8% -$2.94K 0.05% 312
2014
Q1 		$39K Sell
1,269
-3,769
-75% -$112K 0.06% 284
2013
Q4 		$146K Buy
+5,038
New +$147K 0.22% 113

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Thompson Davis & Co's PFE Position: Q3 2022 in Review

Thompson Davis & Co sold out of Pfizer (PFE) in Q3 2022, closing a stake of 8,500 shares — an estimated $446K sold.

Thompson Davis & Co first reported a position in PFE in Q4 2013 and held it in 23 quarters. The position peaked at $1.21M in Q2 2015. 3,088 funds tracked by Wall St. Rank hold PFE as of Q3 2022.

  • Thompson Davis & Co reported no remaining Pfizer position as of Q3 2022 after selling out during the quarter.
  • Thompson Davis & Co sold 8,500 Pfizer shares in Q3 2022, an estimated $446K.
  • Thompson Davis & Co first reported a position in Pfizer in Q4 2013 and held it in 23 quarters.
  • Thompson Davis & Co's Pfizer position peaked at $1.21M in Q2 2015.
  • 3,088 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.

Based on Thompson Davis & Co's 13F filing for Q3 2022, filed 9 Nov 2022.